Published in Hematology Week, August 2nd, 2004
"Present-day pediatric cooperative group acute lymphoblastic leukemia (ALL) protocols cure approximately 80% of patients, a result achieved largely through the use of risk-stratified therapies that employ multiple chemotherapy agents.
"These risk-based therapies utilize host and leukemia traits to select the most appropriate therapy. However, these risk-stratified approaches predict therapy response imperfectly and an important fraction of patients experience relapse or therapy-related toxicity," scientists in the United States report.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.